Know Cancer

forgot password

International Pediatric Adrenocortical Tumor Registry

21 Years
Open (Enrolling)
Adrenocortical Tumor

Thank you

Trial Information

International Pediatric Adrenocortical Tumor Registry

Adrenocortical tumors (ACT) are very rare in children and teenagers. Of all the new cases of
cancer diagnosed each year in the United States and Europe in patients younger than 20 years
old, only about 0.2% are ACT. Studies from several laboratories including St. Jude
Children's Research Hospital have revealed that the majority of children with ACT,
particularly those younger than 4 years of age, have constitutional P53 mutations. Some
mutations, as exemplified by the R337H P53 germline mutation, in which the function of the
mutant protein is relatively preserved, the history of cancer in the carriers and their
families is relatively unremarkable. In other cases, the P53 mutated gene encodes a
functionally-impaired protein that predicts for a pervasive history of familial cancer
(Li-Fraumeni syndrome). Therefore, these observations have implications for genetic
counseling of families with childhood ACT and underscore the importance of
genotype-phenotype correlations in familial cancer syndromes.

The creation of a specific rare tumor registry provides a mechanism to collect information
that cannot be gathered in a single institution. The analysis of the registry data would
permit an overview of the clinical, epidemiological, current treatment standards, and
survival data of these patients and thus create opportunities for research. It also may
facilitate the development of treatment consensus among investigators who register their
patients and help to design future studies. Moreover, the combined COG and IPACTR studies
are expected to provide meaningful insight into the biology of ACT, including clinical
phenotype/genotype relationships, treatment outcome and long-term follow-up data in subjects
with this rare tumor. Finally, it would provide data on the long-term consequences of
exposure to tumor-secreted androgens (found in more than 80% of the pediatric cases) on
children's growth and development.

Inclusion Criteria

Inclusion Criteria (patients):

- Age ≤ 21 years old at diagnosis

- Diagnosis of adrenocortical tumor (adenoma, carcinoma or undefined histology).

- Signed informed consent

Exclusion Criteria (patients):

- Age >21 years old at diagnosis

- Informed consent has not been signed

Parents/Relatives Inclusion Criteria

- Any age

- Diagnosis of malignant tumor

- Signed informed consent

Parents/Relatives Exclusion Criterion

- Informed consent has not been signed

Type of Study:


Study Design:

Time Perspective: Prospective

Outcome Measure:

Collect demographic/medical information, detailed family history of cancer of children/adolescents with adrenocortical tumors, learn more about the clinical and epidemiological aspects, treatment modalities, and outcome of patients

Outcome Time Frame:


Safety Issue:


Principal Investigator

Raul C Ribeiro, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

St. Jude Children's Research Hospital


United States: Institutional Review Board

Study ID:




Start Date:

May 2001

Completion Date:

December 2040

Related Keywords:

  • Adrenocortical Tumor
  • Adrenal Cortex Neoplasms



Stanford University Stanford, California  94305
St. Jude Children's Research Hospital Memphis, Tennessee  38105-2794
Cook Children's Medical Center Fort Worth, Texas  76104
ALL Children's Hospital/St. Petersburg Hospital St. Petersburg, Florida  33701
The Children's Medical Center Dayton, Ohio  45404